Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma (UCDCC#208)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00795665
Recruitment Status : Completed
First Posted : November 21, 2008
Last Update Posted : January 5, 2016
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Genentech, Inc.
Information provided by (Responsible Party):
University of California, Davis

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : December 2015
  Actual Study Completion Date : December 2015
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 July 3, 2018
July 30, 2018
2 October 2, 2018
(Canceled on October 16, 2018)
October 16, 2018
November 14, 2018